EVOK - Earnings call transcript Q4 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Evoke Pharma Fourth Quarter and Full Year 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's call is being recorded.

I will now turn the call over to Daniel Kontoh-Boateng. Please go ahead, sir.

Daniel Kontoh-Boateng

Good afternoon, and thank you for participating in Evoke Pharma's conference call and webcast today. Officer. Dave Commercial Chief Matt Officer President Chief are Quesenberry, Officer; D'Onofrio, today and Chief GIMOTI's from Operating me Gonyer, Executive Evoke's Chris Evoke's With Eversana; and

of By to the If now, read it company's on our page available well Form Investor is have with We website release you a at as Evoke's not, as XX-K press The we evokepharma.com. issued should XX-K, release earlier. Relations the of the is copy encourage press annual on on in release today's report earnings filed which now SEC. available are everyone Form and both also website.

Reform certain by and call, results covered discussed harbor stated could the making safe will Act. note the call those or the listeners implied Litigation these be statements uncertainties Actual to of associated information that, forward-looking during We under that business. management forward-looking caution this the differ today is risks company's statements. provisions due from Please Securities with materially on Private

conference time-sensitive statements SEC These and contained that Evoke's This statements in by subsequent on call cautionary XX-K the releases filings. conference contains qualified annual is and including press Form its filings, are undertakes report information forward-looking the and this date this only any accurate of webcast. as to live no broadcast. revise statements reflect call of the events of after date Evoke to obligation forward-looking update or or circumstances

to the over turn With to David Dave? that, I now would call Gonyer. like

David Gonyer

Thank the this Daniel, call afternoon. you, thanks, everyone, and joining for

fulfilling within needs every mission, is release who a also not XXXX commercially, milestone core marks in it. was which in journey, As just is patient in reach today's Evoke's but ensuring GIMOTI for press described our

fuel daily sales health the this our A so providers, testament as progress to you we've because patients the been from from an progress can tell will organization. stories own the to patient representatives patient and success some and me important. It's tell core it's us our is the help positive us who experiences their on that fuel told care and about why amazing comes basis. a Let efforts hear and countless stories mission

impacts on just to was the week, his like XX-year-old both share out and hospital a about this very to about today, shared who, male that and care gastroparesis, month hasn't just inspiring man single brief type predominantly gastroparesis story had us who it's admission, And severe While a just health diabetes hospital women, life-changing was his not X this gastroparesis. of This I'd visit, starting in battled for of him. shared to GIMOTI, because every provider been that, with he since one. a

care these and suffer that who push best advocates they from payers fight can for possible. so receive stories will It's the this to patients and disease insidious like providers

is of have this Now to that continues just energize heard we many our commitment. affirmations one

often while patients all Now their can or want wait we better the is diagnosed. to coverage. Payers But denying And payers they success, done outright the cost do much before -- not do is be of we're to them. these patients When gastroparesis. diagnose for stories patients then with patient, treatment treatment. there's to too told prescribed, can and can for the get pushing are often, norm treat years also more unfortunately, humbled to providers to and these do to they're receive encourage better

leading studies the the clinical our presentations health III of for value The scientific metoclopramide groundwork, Phase standard. data evidence GIMOTI and of utilization gastroenterology beyond in compared goes at of publication and resource congresses, our plenary hospital the peer-reviewed compelling emergency The real-world GIMOTI and anecdotes. room versus current savings demonstrating reduction oral underscores care the visits, and significant health cost a gold total the to

as compelling and And now straightforward, and be week. outcomes as the very rapid and X GIMOTI bloodstream. as well. GIMOTI oral GIMOTI Our story simple improved relief documented absorption really early provides is shaping symptomatic achieves shows it's in direct to versus up metoclopramide.

drug disease, be an is avoids pills delivery small to absorbed. predictively the intestine deliver through to problem the which into inability The of the the nose

Importantly, metoclopramide GIMOTI, many HRU hospitalizations treatment. because confirming as place the transformative patients were the who medicine not its same utilization were oral reduction in gastroparesis GIMOTI, in experienced they in previously well, resource the switched taking and had visits study or study, to health likely while a doing ER

The the bit prescriptions and happy growing year. let XXX% year-over-year, report highlights and Now some GIMOTI. a demonstrating over dispensed demand XXXX. prescriptions for of clearly the total for a that GIMOTI to turn to by doubled new grew for net revenue me gears I'm XX% increased number we last switch our notable by

augmented XX% depth We base the their by of XX%. by prescribing also while prescriber our amplifying

and our Our Conferences, focus commercial above Digestive targeting achievements selected the by gatherings of College our financial At and the presentations boards our gastroenterology outreach providers, team's driving health both Week for data relentless at respective such as propelled Gastroenterology our American to care important meetings. governing was Disease expectations. plenary

to we to evidence only highlighted resonated importance economic commitment in with efficiency role significantly GIMOTI's a is our as and resource but of reducing ER care payers. perform, and delivering GI care professionals not the at strength reduced outperforming underscores price. health and metoclopramide for and also data a the testament oral visits the This patient This utilization hospitalizations, study

on pharmacy bit enhance transitioned meet robust alignment us our a ASPN's our Furthering better a services. positions our And this strategic to strategic access, and needs, will with in services distribution platform initiatives, ASPN. streamline Chris our patient to moment. little The more we elaborate

We've year dynamic only have therapy. count in but not growth, on the belief GIMOTI, on dividends. back doubled the strategic our patient paid of strengthened investments Looking a

approximately into lean XXXX net million, we projected As a with we're aiming performance. XXXX, tripling nearly our high revenue $XX of

And with to our and talk for me let over commercialization it activities forward that, plans to year. about current Chris turn moving this

Christopher Quesenberry

times. at spoke we about revalidate and providers script. This that prescribing year's cumulative riders initial time. The of which Dave prescribers, confirm to prescriptions denotes commercial have slide to consecutively their or over strategy, close that GIMOTI written have after look more just Dave. X, took that To the acceptance X,XXX more Thanks, a XX% physicians, write more uptake prescribed our and last and also totaled continue GIMOTI,

is potential encouraging of GIMOTI. growth to that a and unabated this our to drug's and new strong to is testament is depth XXXX, prescribers The in for From efficacy grow of also and of highly profile. breadth an adding the standpoint, for simultaneously there significant still do and while or prescriber so-called user-friendly is the indication prescribing, difficult continuing prescribing

is GIMOTI, reached opposite Quite have any We true. not use ceiling of for the

of improves on and share Encouragingly, GIMOTI metoclopramide target gains not throughout that further to grew list, audiences, of progressively the as and specifically stronger metoclopramide of market call metoclopramide time XXXX, slide, across you market showed potential of at as compared move While you the are from look it's -- targeted our the call prescriber similar plan all you look not to important shown those GIMOTI throughout as prescribers oral XXXX. share gastroenterologists.

perform many provide Importantly, our the and procedures for GIMOTI care practitioners in clinic, instead scopes highest to significant gastroparesis who share deciding with time for patients medical is spend or [ a less ]. gastroenterologists as nurse physician of portion with assistants,

the broader reinforce a to offer gastroparesis. performance payer triple we challenge XXXX our our we steadfast, XXXX amongst focus patients is within solid provider to to have -- and and of GIMOTI colleagues in belief a and earned Throughout GIMOTI diabetic beyond, base remains the providers. to me, our XXXX. right believe In excuse or in foundation in our nearly mentioned, objective built As XXXX,

that make GIMOTI we Importantly, metoclopramide the not will health clear nasal and did utilization provided that underscore same have administration route of resource that the reduction matters. oral care

For prescribing. appropriate GIMOTI, to switch we broadening to and patients, providers will deepening ask thereby

the for GIMOTI continue and XXXX. We have this imperative will throughout addressed rate improving fill

prescribing to earned in of We of and it be sent was local a the pharmacy. XXXX because of to a retail much amount prescription significant filled providers unable GIMOTI

will partners guide pharmacy mitigate scripts to network in scripts our We tools capture and to appropriately. a this to use and

and discussions. concerns encourage risks will dyskinesia latent to tardive benefit leverage education and our communication we Lastly, risk clarify for and appropriate increase

appropriate use. untapped Here again, is to there tremendous potential clarify

is for clear GIMOTI request be be are about who appropriate who will We and to inappropriate offered GIMOTI. those

on Tactically, here's these build we plan how to initiatives.

treatment optimal gastroparesis optimized to as continue for will its for nasal We administration. advocate the promote GIMOTI and to due choice

support and are pharmacy will services data. lines to prescriptions mitigate care fall And with currently, distribution to patients. and health with this partnering we utilization qualitative that systems our and our outside We their quantitative organizations reach never leverage

Pharmacy GIMOTI's fill without joining our drug pharmacy ensuring delay. we ASPN our and with treatment receive their patients rates Additionally, need the distribution improving to to gain including access network, extensive they pharmacies, network, specialty will

dyskinesia channels, with Through or also appropriate associated risks to transparency. TD, demystify the persist tardive through education and we'll

involuntary causes effect that to to controlled. of effect ACG the lower previously seen dyskinesia and medication For thought. guidelines commonly select movements face that of antiseptic recent due medications background, side is can't with more to side this than metoclopramide tardive older risk body is The be indicate exposure one's the

In X%. likely fact, less than it's

confidence analysis GIMOTI prescribing and And shifting from appropriate our to with are By reset only including safety a avoid, the backed XXXX will ACG's confirmed to clear patients low perceptions incidence, by comprehensive in and fear at-risk and DDW physicians to which encourage at the profile. a informed of presenting presented conclusion. data, We we claims understanding patients to prescribe monitoring. believe this narrative

pharmacy accessibility GIMOTI, to by we've As of the strides our evolving and and of utilization capabilities. we build demand taken deliberate distribution GIMOTI enhance

with and to on Our processes journey which us swiftly Eversana manual EvokeAssist longer or though fulfillment implement had the began it allowed Pharmacy, relied system times.

refills me, medical expedite automated [ upgraded to process. workflows, with significantly filling integrating progress seamlessly refills we ], we automatic excuse prescribing, our -- VidaCare to enabling electronic As the facilitating capabilities,

next the automation, Asembia, authorizations, patients our process to but Asembia providers, through the prior communication the and prescription promptly. their offers text, on also ensures advancements, we've streamlines prescription via for our status complete health transparent patient accessible taken receive portals real-time with physicians to care end-to-end patients. Building not distribution only Now This and medication previous including level.

patient infrastructure robust Asembia's further positively and scale importantly, us pharmacy and reach to network outcomes. impact Most expansive our position

optimizing signify embody patient strategic GIMOTI the commitment unwavering our access and These our to dedication enhancements to care.

as our Asembia, XXXX, known also initiated November clear enhancing lever it's just only [indiscernible]. we've our for identified Although in we've with of critical Pharmacies, ASPN a partnership

we've strategy conversion Through refined the in seen a ASPN tangible communication our process within platform, uptick and rates. and optimization

we jumps exclude overall been and there's process prescriptions Specifically, of a XX%. and prescriptions, impressive new improvement more when in to filled, increase the even X% number

towards Moreover, patient increase the efficiency programs, affordability our we're seeing significant an need with process, GIMOTI. streamline to inherent testament are proposition reimbursed that on shift a in without X% a greater for a sales value

Additionally, communication not as start only results. transparent to our is With reduction on there's been commitment GIMOTI with prescriptions, and in that their of a continue patient-initiated patient yielding patients XX% underscoring ASPN's abandonment rapid ensuring focus ASPN, to appropriate. treatment

patient in and bottom are vital providing improvements These metrics all to GIMOTI to adherence, will benefits real access not numbers. can are mission just These of benefit They represent who also to the our which it. from line. fall

we leveraging over the our X,XXX remains GIMOTI electronic within actively our care of pharmacies successfully are write commitment point this prescribed initially a those medical addressing As professionals retail technology intercepting leakage scripts effectively. reaches ASPN. and to we in fortify in prescription reminding to prescriptions made ensuring them headway to critical. to health be records, directly including ASPN we to redirected need, retail that pharmacy, to of pharmacy, Using intended By approach, at successfully

have patients believe we improving recently communication patient cementing GIMOTI's in EMR pharmacists and our prescribers, with in outcomes. coverage effort We presence and critical partnership is market expanded Based that this on the partners. with strategic other success, alike

all now health new is in messaging partners have Dr. record systems, of and added nearly we electronic half Our enabled in

direct. prescription is at GIMOTI that of First and more month, this the and even clear pathway ensuring ConnectiveRx beginning

were hospitalizations by GIMOTI similarly GIMOTI metoclopramide. emergency reduced evidence of resource slide Image we GIMOTI that using qualitative reduced in department taking real-world oral left-hand inpatient last showed in unveiled side health also the versus studies visits utilization demonstrated XX% compared And patients and of with significantly value to the addressing shows on XX% diabetic year, metoclopramide. Now care were those oral quantitative patients it X of the in gastroparesis. the by

or hospitalizations also patients a win is things That The a XXX a doing significant reductions spend over and we time simple period. patients. for XX for win fewer home with XX X-month experienced GIMOTI at more that taking patients who ER The be families fewer visits all granted. their can will for take significant

costs, costs lower. right-hand side medical numerically larger sum in despite to the the and costs which GIMOTI, significantly looking slide, costs of health Amazingly, pharmacy care prescription the the of encounters, is total were all

period oral a In of time. X-month for those fact, patients GIMOTI, over over $XX,XXX taking than taking lower generic metoclopramide

its about system. illustrates patient potential significant and the role These emergency in option, benefits clinical proposition, reducing marking providers volumes financially daily cost life our health choice Moreover, reduction payers. only a in value economic profound care sets its reinforce impact. GIMOTI's is and data and enhancing GIMOTI's visits superior treatment health substantial on it care hospitalization savings department The burden the highlight for and also patients, not responsible speaks but

I outcomes. standard effectiveness agent, evaluate than of would for is how breakthrough modality demonstrating It's for with more other treatment, argue gastroparesis efficacy for used patients this precedent types gastroparesis, win-win. data and setting new No debilitating these and disease a we that treatment disease. no the of cost has in a this other progressive in fact, a

And test so we're going to data with payers. these

We're health are provocative the data these data them GIMOTI with the to for the the same PBMs research, but decisions. utilization might elements right that fact, that alike In of enough what this coverage midst doing HRU showed resource we has up hearing wrapping how I potentially from insurers, coverage payers asking market slide. based our IBMs you and impact in impact care now on through previous decisions and research, that data we're is on

decision, who with portion outright significant indicated them additional affirming another costs to make currently presented coverage data of expressing that them XX% A payers evidence GIMOTI would willingness reconsider are XX% and not and of covering savings. reconsider of with

conviction cost reduced reduction factors prescription hospitalization to requirements underpin coverage need key rates, overall robust feedback who for of this reviewed the that are lower do drivers Additionally, analysis of obtaining further our We credibility. evidence currently perspectives. of for This and process the continued such of evidence lengths, detailed ease and providing more GIMOTI, the nearly can saving focusing Payers preliminary would peer data half the it recognize payers readmission burden. for on bolsters GIMOTI. shift provide for looking as documentation for generation,

of of Additionally, pivotal the medical value unnecessary burden assurance enhance GIMOTI. safety and components reduction of that procedures of the the illness, would in avoidance story are

body. to the what the Now a might causes movement that involuntary main providers among have in is commonly fact prescribe the one it for Certainly, occur TD TD with of GIMOTI similar dyskinesia, warning tardive hesitancy their with a can box to to medicines. carries label. oral reasons disorder for but that metoclopramide GIMOTI is is or more movements metoclopramide, associated face antipsychotic

TD deal is regular understanding how basis, gastroenterologists. refractory appreciate don't for a or with often is it that it there it is many We've metoclopramide for come significant apprehension on Their patients. to a in more a and mystery to avoid We gap the leading using and their of occurs. reserve TD

of We narrative need avoiding to educated afraid and being this to one and from shift monitor.

the prescribing and understanding of guardrails box who excellent information We road GIMOTI. thereby, providers a a the from will clear benefit many avoid label that the within to the leverage it map our develop provider information is warning and, appropriate are help the can and at help to risk label see patients patients to

HCPs data most guidance than and likely which of metoclopramide, recent with less risk TD is around will again, the the with it X%. We update

clarify to We we been TD will reported and program October has of in in or avoid educate on the since that, clinical the XXXX. date, of to patients GIMOTI launch development which will no

for GIMOTI to our when moving forward can informed intensify educational make benefit/risk their will considering assessments We ensure that efforts providers patients.

patients on our sales tardive education includes through engaging providers force make providing Our choices. so the And targeted multipronged informed and educating dyskinesia, their approach and specialists resources. -- they team symposia, latest with through our with sales motility insights empowering lastly, can providing

but psychiatry of neurology KOLs and [ ] to is own like ourselves inform MacAlister expanded of our We New Institute with importantly, educate Peter have within And to efforts. continue inform engage England and specialties, KOLs and Neurology gastroenterology, the within to Headache. education this

patient our to is health from GIMOTI, informed commitment and supporting to is well-being. use and its every dedication Our stakeholder, fully reinforcing patients, care to appropriate that about ensure thereby providers safety

I'll financials review remarks. turn to the that, Matt and over closing call to With the

Matthew D'Onofrio

for again, quarter into fourth again XXXX full Thanks, of right for the results. . the year financials today. and joining us thanks books get Chris. everyone Once I'll and

were quarter, with $XXX,XXX million compared approximately Dave or share, product quarter XXXX. for or sales And was mentioned, of million, fourth $X XXXX. $X.XX per $X.XX the million share with $X.X quarter approximately As fourth net the the net compared during per $X.X for fourth the loss of

year And with $X.XX compared December $X.X for December XX, the for ended was the share, of XX, net or XXXX, XXXX. per or sales ended year compared $X.X as $X.XX the For $X.X approximately December product million ended net per XX, a with million approximately loss XXXX. approximately the $X.X net were year share loss million million,

have year-over-year revenue to Dave prescription that with to through with was comparing Pharmacy, in previously product, improvements net from data metoclopramide partnerships showing The visits didn't and Chris elaborated to exceptional ability in GIMOTI due XXXX GIMOTI providers oral the captured ER in and as fewer and higher to to earlier. the sent the increase oral. sales ASPN service real-world We GI head-to-head compared resulting community pharmacies in sharing pharmacy product order sales prescriptions hospitalizations retail with

the compared development $XX,XXX expenses and $XX,XXX fourth quarter quarter for the fourth of XXXX. of XXXX, totaled Research for to

the $X.X million, the $X.X year compared approximately were expenses XXXX, approximately million research development with For full prior for and year.

selling, XXXX, the XXXX. For were of $X.X and million for $X.X approximately quarter fourth fourth with million, administrative general of quarter expenses the compared

year XXXX. ended expenses were $X.X year XXXX, $XX.X selling, December for the approximately million administrative versus and ended XX, the XX, approximately For million, general December

SG&A royalty primarily higher profit marketing costs. from resulted The costs year-over-year and sharing increase Eversana in

GIMOTI to profit progress obtained continue sales from expect the and we with as the will the administrative general selling, GIMOTI. from expenses that in net Eversana of of commercialization reimburse we and future We the increase

million, XXXX, of for year $X.X same the year approximately million full million with with approximately quarter December $XX.X expenses $X.X compared of XX, operating XXXX period million, And $XX.X compared XXXX. approximately total Total expenses for the were were for of XXXX. fourth the ended the for operating

As operating the based future offering plan as with GIMOTI, from fund February sales into will net $X.X of XXXX, fourth were cash XXXX, believe, public XXXX. that that the sufficient to be that cash cash, approximately million. equivalents from as We recent cash December operations and of current cash on our the in the proceeds executed our including product at existing well we XX, of quarter flows equivalents,

increasing the renewals year new and February, the higher has company changing While the meet patients, their deductibles prescription cover other of for typically trends beginning we of prior authorizations. of for are expenses through the seeing to discounting co-pay coverage and and needing patients to because

also may care what our pharmaceutical with were is have this Healthcare clear this, It or see watching entities been we've Recently, Change the business. impact all situation to that not impacted closely health just by Evoke. companies on

were to outage, to solution or prescribing patient Eversana that care our put the providers' started across inability the impact a eligibility partners are new place claims health other week submit and to Although and within experts industry of Evoke change benefits has able we in they from support. a hearing brands

lastly, GLP-X the increased association could number or gastroparesis. use market gastroenterology on We new last GLP-X agonist. particularly the from agonist over the of months several effects with people opportunity interest has products, agonist believe suffering in the of that our glucagon And ongoing the gastroparesis. those is gained peptide the to some side attention attributed increase a was Currently

several including Slow emptying similar symptoms postprandial control reduction gastric potentially mechanisms, enhancement emptying gastroparesis. intake. lead to gastric glucose-dependent secretion, to insulin glucose affect may and of of food through agonists receptor GLP-X glucagon and slowed

specifically attributing associated the is of that evidence in was with compared of published of Medical increased loss causing pancreatitis, American GLP-Xs obstruction use bupropion/naltrexone gastroparesis. agonist a weight found gastroparesis Journal GLP-X for the risk of with the use bowel definitive study and limited, Although Association recent

the rate gigantic population these to from GLP-Xs in relatively considering population, the impact been a large be have While gastroparesis future. adverse expected events an the very X% incidence have rare, with even on market treated GLP-Xs could

And questions. with remarks, I'll our operator, over that, and for formal we've it completed turn

Operator

question I-Eh & a Instructions] from from do We Laidlaw Jen have [Operator Company.

Yale Jen

year. this And congrats here. I've on performance X X or questions got the

as one how distribution, bit a on first you Pharmacy The service little has more about is, XXXX in you color on the terms that could but you that of ASPN based your give versus will improved some, have impact your XXXX mentioned evidence? elaborated

David Gonyer

that? take do Chris, you want to

Christopher Quesenberry

Sure. for the thanks, I-Eh, question. And

and aspects efficient us. that result delivers help their through abandonment get fewer communication prescriptions. with patients patients. ASPN of different of One more couple return to So a They calls platform of in is phone

leakage not is that prescription key -- in that's back. for So fact, calling to us is reason funnel, our in the patients a largest

they So significantly will reduce that.

is is, thing payers have relationships those they second into integrated The that systems. payer with strong are and

authorizations. again, a processing from in prescriptions authorizations approval scripts, efficiency higher And which prescriptions yielding mean increased a approval prior their and prior those reimbursed is help will that of revenue electronic authorizations So certainly those gain percentage us perspective. for prior

one and about, excited to pharmacies contract Medicaid. ASPN piece, have access our last payers, that too, the will our aspect important we to including in an network are we're us which of Medicaid is give that And is strong for adding be that growth pharmacies, to pharmacies network XXXX. And going fact through with the the

Yale Jen

a more in what local the or a tack here, -- distribution on geographic of more United just terms the nationally? maybe pharmacy, distribution States, regional kind question, to in of this answer or And

Christopher Quesenberry

have pharmacies states. in coverage all XX current Our contiguous

that good a perspective. we So have coverage from

imagine, you the you pharmacy states have As a can in of Medicaid, local product. require distribute to to terms some order in

to might certain prescription, us. approval to so. going to even states, that's have deliver important be a are why adding those we So pharmacies we of can't In do though

will So in pharmacies our adding and that especially coverage, Medicare Medicaid. augment strategically we're

Yale Jen

XXXX. we guidance how and that Or a for Okay. the think terms conservative? [indiscernible] as little sales here effect? Should consider bit this should we then Great. question And overall maybe is in of last guidance about

Matthew D'Onofrio

we terms Matt. past. in believe doable, on -- we've there's that said further the earlier, this further opportunity We putting as going Chris we're in believe guidance. of what to point. unlimited this I that Yes, We're seen not comment of is at is Yes, guess out what there growth any terms in

currently physicians' some significant yet with. curtailing any that any seen in we're of no We're haven't share with way We of meeting targets the interest. market sort reaching of

So we and very appropriate providing time. we're guidance is think this this what at and that's doable,

Yale Jen

here. Okay. Maybe question just more one

side GLP-X, mentioned one is of As effects. you about gastroparesis expected

actually Just taking of of now, oral GLP-X that you subcu prescription curious, patients the up any the that drug? also to have whether ever treated be or

Matthew D'Onofrio

Yes. up. I-Eh, it's a appreciate opening great you this really question. I

I think GI to related it it's to important gastroparesis for the one really clearly several does and gastric -- also people things down the is. of GLP-Xs, other key by that the action is different do cravings But understand they definition, mechanisms of slow satiety track. curtailing, sort emptying. of what And things. That delayed

that's or are patients with not this. and or of very we're And sort the completely new whether GLP-X or coming then on indication addition mild And patients the So was for not novo is unmasked mostly -- gastroparesis beforehand, diabetic, of this exacerbated who had those de what it issues, perhaps. original exactly. certain then

totally stories had of de think it's We just days that. have they it's early novo, read no online still claiming around persons some that I beforehand. problems

write her with not do pursue it in to choose receive of in will nature. patients, [ and not from has whatever was authorization the with with That so met symptoms and used nurse that have did physicians own promoting that. treat significant of been whether I myself then herself herself they to terms used And course, for BEGOVY decision, her of GIMOTI we for to her anything symptoms happen ] prescriptions practitioner associated fact. of these GIMOTI have reason we're We who found after for or out treatment with and any a

these at GIMOTI are they're either physicians also the about Because help asking it utilizing have do -- they very mimics to patients do gastroparesis with questions from we or conferences, hearing And problems. keenly.

So may, ways think be their these physicians deal with own are fact, which in to problems gastroparesis. starting again, I find to

David Gonyer

is I-Eh, And this Dave.

out. to thing one Just I'm going point

was just forecast in our not assumptions this upside. for So be XXXX,

that's I want to So as make clear sure well.

Yale Jen

performance And congrats quite nice so great. That's a far. on again, Okay.

Operator

or today's to call. Q&A back any the of Matt like now I call over portion the D'Onofrio remarks. additional This concludes would for to turn closing

Matthew D'Onofrio

Well, represents our building a the in million strengthening to in momentum support you. investments for that XXXX, health is has that net the care value nearly of our again strategy, from GIMOTI. guidance Thank belief last XXXX. year. forecast for revenue And and $XX Yes. from the on of increase This been threefold central target providers'

improved execution year rates for the and evidence your you of strive GIMOTI's to our the continue forward of of outstanding really all the depth continuing that breadth sharing brand. support. for while progress continued invest prescription the to we over appreciate look Again, and in supports to We course

time, we'll and much, very you close Thank this at operator.

Operator

today's and XXXX Evoke This concludes Pharma's Quarter and Fourth Webcast. Full Year Earnings Call

You may a have time. wonderful your And at disconnect this lines day.

Evoke Pharma (EVOK) 14 Mar 242023 Q4 Earnings call transcript